Nina Capital, a pioneering venture capital firm dedicated to healthcare transformation through technology, announces the first close of its €50 million Fund III. The new fund will propel Nina Capital’s total assets under management to over €100 million, reinforcing its position as a leading international investor driving impactful healthcare innovation.
Fund III is anchored by contributions from limited partners such as Boston-based wealth management firm Seven Two Partners, professional family offices, foundations, corporations, and experienced high-net-worth individuals across Europe and the United States. The support of such a strong, international base of investors underscores the global belief in Nina Capital’s mission: to empower need-driven founders reshaping healthcare systems with information technology.
"Healthcare is at the forefront of a transformative era, where groundbreaking innovations are creating immense opportunities for both patient impact and investors," said Andrew Macken, Managing Partner at Seven Two Partners. "For the best outcomes in this complex industry, we believe that it is important for managers to find great founders who are working on solving these significant problems and for those managers to help these businesses grow. We are impressed with the work that Marta and her team have accomplished and excited to see what Nina Capital has in store to reshape the future of healthcare.”
With Fund III, Nina Capital is set to build a new portfolio of investments across Europe, North America, Israel, and, for the first time, Australia. From pre-seed to Series A, the fund will write initial checks ranging from €250,000 to €1.5 million, with reserves to support portfolio companies through follow-on funding.
Building on the success of its previous funds, Nina Capital has already made its first Fund III investment: Sonar Mental Health, a US-based mental health platform serving school districts nationwide that assists students through a combination of AI and support from certified counselors. With two more investments in the pipeline for early 2025, Fund III reflects Nina Capital’s unwavering dedication to technologies that create meaningful, measurable healthcare impact.
Nina Capital’s track record speaks for itself. Startups from Fund I achieved an above 80% graduation rate from seed to the next stage, while Fund II portfolio companies collectively grew revenue almost 5x within two years from the initial investment. This momentum is fueled by the firm’s deeply specialized team and ability to identify and scale impactful healthcare innovations.
Dr. Marta G. Zanchi, a former director of Stanford Biodesign's Digital Health initiatives and medical technology executive, and Marc Subirats, an accomplished entrepreneur whose telemedicine company Advance Medical was acquired by Teladoc Health, bring relevant hands-on experience to their roles as General Partners. "This fund is the next natural chapter of our story, building on a proven strategy and team," said Subirats.
The team is further strengthened by Bob Schulz, Nina Capital’s newly appointed Chief Partnership Officer based in the United States. Schulz, the founder of Health Enterprise Partners, joins a seasoned network of Venture Partners and Advisors as the firm scales its operations globally.
Promotions in the firm also reflect its commitment to excellence. IESE Business School alumni Yahel Halamish and Sebastian Anastassiou, who joined as Associate Interns four years ago and later became Principals, have been promoted to Partners, showcasing Nina Capital’s focus on developing leaders from within.
Like previous funds, Fund III will focus on three critical healthtech areas:
1. Clinical Innovation and Education – Empowering new solutions in diagnostics, medical devices, and clinician training.
2. Healthcare Infrastructure – Transforming data-driven processes in preclinical R&D, clinical trials, pharmaceutical logistics, and manufacturing.
3. Clinical Pathways and Health Data – Improving care delivery through tech-enabled services and operational efficiencies.
"Healthcare is at an inflection point. We see extraordinary opportunities for innovation to break down inefficiencies, increase access, and improve outcomes. Fund III solidifies our commitment to finding and supporting the boldest minds tackling healthcare’s most urgent challenges," said Dr. Zanchi, Founder and Managing Director at Nina Capital. "Our mission is clear: to find and support the founders who are solving timely and compelling healthcare needs, blending technology innovation with sound business models built on a solid understanding of healthcare market incentives and constraints."
About Nina Capital
Nina Capital is an international, specialized venture capital firm investing in healthcare transformation powered by information technology and led by need-driven founders. Focused on pre-seed and seed-stage investments and guided by deep industry experience, Nina Capital supports health technology solutions that drive lasting healthcare impact. Nina Capital’s diverse, multinational, and multidisciplinary team is led by former healthcare technology founders and operators and combines expertise from numerous healthcare and technology sectors. Since 2019, Nina Capital has invested in 50 companies across nearly 20 countries, touching the lives of over 10 million people through healthcare technology innovations.
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
